Bimzelx
Biological
UCB, Inc.
Total Payments
$14.1M
Transactions
69,538
Doctors
14,926
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $12.5M | 62,459 | 14,352 |
| 2023 | $1.7M | 7,033 | 4,162 |
| 2022 | $1,972 | 40 | 20 |
| 2021 | $60.00 | 1 | 1 |
| 2020 | $100.80 | 5 | 2 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5.3M | 1,955 | 37.7% |
| Unspecified | $3.9M | 283 | 27.6% |
| Consulting Fee | $2.7M | 929 | 19.4% |
| Food and Beverage | $1.7M | 63,756 | 12.2% |
| Travel and Lodging | $427,727 | 2,615 | 3.0% |
Payments by Type
General
$10.2M
69,255 transactions
Research
$3.9M
283 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 3, open-label, parallel group, multicenter, extension study evaluating the long-term treatment of bimekizumab in study participants with moderate to severe hidradenitis suppurativa | UCB SA | $1.2M | 1 |
| A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS | UCB SA | $1.1M | 1 |
| A MULTICENTER, OPEN-LABEL STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS | UCB SA | $635,392 | 2 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, SECUKINUMAB-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS. | UCB SA | $397,139 | 1 |
| A PHASE 3B EXPLORATORY MULTICENTER OPEN-LABEL STUDY TO EVALUATE THE EFFECT OF BIMEKIZUMAB ON GENE EXPRESSION BIOMARKERS IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS | UCB SA | $178,588 | 0 |
| A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS | UCB SA | $153,264 | 2 |
| A MULTICENTER, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB COMPARED TO USTEKINUMAB IN CHILDREN AND ADOLESCENTS FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH MODERATE TO SEVERE PLAQUE PSORIASIS | UCB SA | $98,034 | 0 |
| A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. | UCB SA | $83,662 | 0 |
| Cohort Study to Evaluate Fetal and Infant Outcomes Following Maternal Exposure to Bimekizumab for Treatment of Psoriasis during Pregnancy | UCB SA | $66,097 | 0 |
| A MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY TO ASSESS THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF TWO DOSES OF BIMEKIZUMAB IN ADOLESCENT STUDY PARTICIPANTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS | UCB SA | $9,969 | 0 |
| Patient diagnostic journey and time to diagnosis in axial spondyloarthritis- A retrospective cohort study using US claims data | UCB, Inc. | $2,700 | 1 |
| Long-term efficacy and safety of bimekizumab and other biologics in moderate to severe plaque psoriasis- Updated systematic literature review and network meta-analysis | UCB, Inc. | $2,300 | 1 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, ACTIVE REFERENCE (ADALIMUMAB) STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS | UCB SA | $1,500 | 0 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA | UCB SA | $1,000 | 0 |
| Achievement of Minimal and Very Low Disease Activity Among Patients with Psoriatic Arthritis Initiating Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the CorEvitas PsA/SpA Registry | UCB, Inc. | $820.00 | 1 |
| Adalimumab Drug Survival and Predictors of Discontinuation in Hidradenitis Suppurativa | UCB, Inc. | $820.00 | 1 |
| Unmet Criteria for Achieving Minimal and Very Low Disease Activity Among Patients with Psoriatic Arthritis Initiating Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the CorEvitas PsA/SpA Registry | UCB, Inc. | $820.00 | 1 |
| Residual burden in adalimumab-treated patients with hidradenitis suppurativa | UCB, Inc. | $420.00 | 1 |
| Patient and physician preferences for attributes associated with biologic treatments for hidradenitis suppurativa | UCB, Inc. | $400.00 | 1 |
Top Doctors Receiving Payments for Bimzelx — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Dermatology | Los Angeles, CA | $85,310 | 68 |
| , M.D | Dermatology | Chicago, IL | $81,588 | 74 |
| , M.D | Dermatology | Sioux Falls, SD | $80,086 | 65 |
| , MD | Legal Medicine | South Jordan, UT | $78,208 | 88 |
| , MD | Rheumatology | Seattle, WA | $77,215 | 50 |
| Michael Cameron | Dermatology | New York, NY | $76,851 | 78 |
| , M.D | Clinical & Laboratory Dermatological Immunology | New Orleans, LA | $76,373 | 60 |
| , M.D | MOHS-Micrographic Surgery | Bakersfield, CA | $76,355 | 45 |
| , MD | Student in an Organized Health Care Education/Training Program | New York, NY | $75,177 | 55 |
| Henry Yu | Physician Assistant | Bronx, NY | $73,303 | 121 |
| , MD | Dermatology | New York, NY | $72,253 | 75 |
| , MD | Dermatology | Pembroke Pines, FL | $71,343 | 84 |
| , PA | Medical | Woodstock, GA | $67,248 | 89 |
| , MD | Dermatology | Margate, FL | $65,839 | 42 |
| , DO | MOHS-Micrographic Surgery | Las Vegas, NV | $64,693 | 43 |
| , MD | Clinical & Laboratory Dermatological Immunology | Los Angeles, CA | $64,030 | 30 |
| , MD | Procedural Dermatology | Phoenix, AZ | $61,357 | 100 |
| , PA C | Physician Assistant | Calhoun, GA | $58,799 | 91 |
| , D.O | Dermatology | Fort Worth, TX | $58,405 | 71 |
| , MD | Dermatology | Cleveland, OH | $57,519 | 41 |
| , MD, PHD | Dermatology | New York, NY | $56,833 | 35 |
| , M.D | Specialist | Redding, CA | $55,095 | 48 |
| , MD | Rheumatology | Carthage, MO | $54,294 | 55 |
| , M.D | Dermatology | Charleston, SC | $51,583 | 65 |
| , M.D | Dermatology | Exton, PA | $50,852 | 42 |
About Bimzelx
Bimzelx is a biological associated with $14.1M in payments to 14,926 healthcare providers, recorded across 69,538 transactions in the CMS Open Payments database. The primary manufacturer is UCB, Inc..
Payment data is available from 2020 to 2024. In 2024, $12.5M was paid across 62,459 transactions to 14,352 doctors.
The most common payment nature for Bimzelx is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($5.3M, 37.7% of total).
Bimzelx is associated with 19 research studies, including "A Phase 3, open-label, parallel group, multicenter, extension study evaluating the long-term treatment of bimekizumab in study participants with moderate to severe hidradenitis suppurativa" ($1.2M).